Outcome measures | No. of observations (no. of patients) | RS versus non-RS | Aspirin versus nonaspirin | ||
---|---|---|---|---|---|
Relative risk^{a} (95% CI) | P | Relative risk (95% CI) | P | ||
Total number of polyps in rectum and sigmoid | 215 (116) | 1.05 (0.73–1.49) | 0.80 | 0.77 (0.54–1.10) | 0.16 |
Crypt width | 95 (58) | 1.03 (0.93–1.13) | 0.60 | 0.95 (−0.15 to 0.04) | 0.28 |
Crypt length | 95 (58) | 1.01 (0.93–1.09) | 0.86 | 1.08 (1.00–1.16) | 0.04 |
Mean total CCP | 95 (58) | 1.28 (0.94–1.73) | 0.12 | 1.37 (1.00–1.86) | 0.05 |
Mean number of MIB1-positive cells^{b} | 116 (78) | 1.02 (0.89–1.16) | 0.82 | 0.99 (0.87–1.14) | 0.93 |
Hemicrypt cells^{b},^{c} | 116 (78) | −0.82 (−5.05 to 3.42)^{c} | 0.71 | 3.67 (−0.55 to 7.90)^{c} | 0.09 |
NOTE: All models adjusted for first result and time on intervention (years).
↵^{a}Estimated as the exponential coefficient of the intervention effect in the random effects model.
↵^{b}Adjusted for calendar time to account for possible effect of differences in storage time of these samples before analysis; MIB1 is the antibody used in staining for Ki67.
↵^{c}Variable not logged, coefficient not exponentiated.